Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Kroger Co.
KRConsumer StaplesGenerated Jul 5, 2026, 08:09 PM UTC
KR (Kroger Co.) analytical snapshot. Revenue grew +8.8% YoY to $150.04B. Net margin at 1.44% (expanding ▲). Return on equity 26.12%, ROA 4.11%, ROIC 12.80%. Market cap $35.67B at $58.22 per share. Trailing P/E 19.67, P/S 0.24, P/B 5.51. EV/Operating income ≈ 15.56 (EV $48.17B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -16 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Market cap
$35.67B
612.65M shares
Price
$58.22
NYQ
P/E (ttm)
19.67
Revenue (FY)
$150.04B
YoY +8.8%
Net margin
1.44%
▲ 0.09pp
Free cash flow
$2.88B
1.92% margin
Risk level
Elevated
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score -0Stable
80% conf
Revenue grew +8.8% YoY to $150.04B. Net margin at 1.44% (expanding ▲). Return on equity 26.12%, ROA 4.11%, ROIC 12.80%.
- Revenue grew +8.8% YoY to $150.04B.
- Net margin at 1.44% (expanding ▲).
- Return on equity 26.12%, ROA 4.11%, ROIC 12.80%.
- Gross margin 0.00%, operating margin 2.06%.
- Free cash flow margin 1.92% ($2.88B).
- Net income up ▲ +30.8% YoY.
- Debt/equity 2.38, current ratio 0.79, net debt $12.51B.
- Asset turnover 2.98 — capital efficiency.
Revenue (FY)
$150.04B
YoY +8.8%
Net margin
1.44%
▲ 0.09pp
ROE
26.12%
ROA 4.11%
ROIC
12.80%
EPS (diluted)
$2.96
FY2025
Free cash flow
$2.88B
1.92% margin
Debt / equity
2.38
Cash $2.87B
Current ratio
0.79
Equity $6.47B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2015 | — | — | — | — | — | — | 28.07 |
| 2016 | — | — | — | — | — | — | 25.34 |
| 2017 | — | — | — | — | — | $1.57B | 30.44 |
| 2018 | $115.34B | — | 0.00 | 2.99 | 1.71 | $573.0M | 28.50 |
| 2019 | $123.28B | +6.9% | 0.00 | 2.12 | 1.55 | $604.0M | 24.18 |
| 2020 | $121.85B | -1.2% | 0.00 | 2.15 | 2.55 | $1.20B | 36.15 |
| 2021 | $122.29B | +0.4% | 0.00 | 1.84 | 1.36 | $1.54B | 17.32 |
| 2022 | $132.50B | +8.4% | 0.00 | 2.10 | 1.95 | $3.95B | 27.35 |
| 2024 | $137.89B | +4.1% | 0.00 | 2.52 | 1.20 | $3.58B | 16.48 |
| 2025 | $150.04B | +8.8% | 0.00 | 2.06 | 1.44 | $2.88B | 26.12 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| May 24, 2025 | $45.12B | — | — | 1.92% |
| Aug 16, 2025 | $79.06B | — | +75.2% | 1.87% |
| Aug 16, 2025 | $33.94B | — | -57.1% | 4.35% |
| Nov 8, 2025 | $112.92B | — | +232.7% | 0.14% |
| Nov 8, 2025 | $33.86B | — | -70.0% | 0.46% |
| May 23, 2026 | $46.12B | — | +36.2% | 1.96% |
Revenue (annual, SEC 10-K)
2015: 0
2016: 0
2017: 0
2018: 115,337
2019: 123,280
2020: 121,852
2021: 122,286
2022: 132,498
2024: 137,888
2025: 150,039
2015
2016
2017
2018
2019
2020
2021
2022
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2015: 0
2016: 0
2017: 1,568
2018: 573
2019: 604
2020: 1,197
2021: 1,536
2022: 3,950
2024: 3,576
2025: 2,884
2015
2016
2017
2018
2019
2020
2021
2022
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Mar 31, 2026. Latest quarterly report (10-Q) filed Jun 26, 2026. 11 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Mar 31, 2026.
- Latest quarterly report (10-Q) filed Jun 26, 2026.
- 11 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Kroger Co.; broad institutional reporting.
- Recent filers include BERKSHIRE HATHAWAY INC (BRK-A, BRK-B), TradeLink Capital LLC, SILVER CAPITAL MANAGEMENT LLC.
- 4 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 16 recent 13G passive institutional ownership notices.
Latest 10-K
Mar 31, 2026
Annual report
Latest 10-Q
Jun 26, 2026
8-K (recent)
11
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
4
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | May 15, 2026 |
| TradeLink Capital LLC | 13F-HR | Aug 3, 2015 |
| SILVER CAPITAL MANAGEMENT LLC | 13F-HR | Nov 17, 2009 |
| BERKSHIRE HATHAWAY INC (BRK-A, BRK-B) | 13F-HR | Feb 17, 2026 |
| HALCYON OFFSHORE MANAGEMENT CO LLC | 13F-HR | Nov 18, 2002 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jul 1, 2026 | 8-K | FORM 8-K |
| Jun 26, 2026 | 8-K | FORM 8-K |
| Jun 18, 2026 | 8-K | FORM 8-K |
| May 27, 2026 | 8-K | FORM 8-K |
| Mar 5, 2026 | 8-K | FORM 8-K |
| Feb 9, 2026 | 8-K | FORM 8-K |
| Dec 4, 2025 | 8-K | FORM 8-K |
| Nov 18, 2025 | 8-K | FORM 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -72Deteriorating
62% conf
5 risk signal(s), 1 positive signal(s) detected from XBRL filing diff analysis. The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
- Leverage is building — debt rising while equity contracts: Long-term debt grew +40.9% while stockholders equity declined -17.5%. The debt-to-equity ratio is deteriorating, increasing financial risk and interest burden. This may constrain future borrowing capacity.
- Going concern doubt: The term "going concern" appears in 26 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- Material weakness in internal controls: The term "material weakness" appears in 25 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Substantial doubt about ability to continue in latest filing: The term "substantial doubt" "ability to continue" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 11 filing(s).
- Operating cash flow exceeds net income: OCF is 3.14x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Endogenous analysis: The combination of explicit "going concern" language in the filing with deteriorating cash flow or rising leverage is a severe warning signal — the company's own auditors have flagged doubt about the ability to continue as a going concern.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Substantial doubt about ability to continue, Restatement of financial statements.
- Ongoing high-severity risk language: Going concern doubt, Material weakness in internal controls.
Revenue
$150.04B
+8.8% YoY
Operating income
$3.10B
-11.0% YoY
Net income
$2.16B
+30.8% YoY
Operating cash flow
$6.79B
+9.7% YoY
Capex
$3.90B
+49.3% YoY
Total assets
$52.62B
+6.0% YoY
Total liabilities
$44.34B
+11.9% YoY
Long-term debt
$15.91B
+40.9% YoY
Filing quality score
70/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $137.89B | $150.04B | $12.15B | +8.8% |
| Operating income | $3.48B | $3.10B | $-381.0M | -11.0% |
| Net income | $1.66B | $2.16B | $509.0M | +30.8% |
| Operating cash flow | $6.19B | $6.79B | $598.0M | +9.7% |
| Capex | $2.61B | $3.90B | $1.29B | +49.3% |
| Total assets | $49.62B | $52.62B | $2.99B | +6.0% |
| Total liabilities | $39.61B | $44.34B | $4.73B | +11.9% |
| Long-term debt | $11.29B | $15.91B | $4.62B | +40.9% |
| Cash & equivalents | $1.01B | $3.96B | $2.94B | +290.0% |
| Stockholders equity | $10.04B | $8.29B | $-1.76B | -17.5% |
| Interest expense | $544.0M | $571.0M | $27.0M | +5.0% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | AdvertisingExpense, AllocatedShareBasedCompensationExpense, AmortizationOfIntangibleAssets, AssetsHeldForSaleLongLivedFairValueDisclosure, AssetsHeldForSaleNotPartOfDisposalGroup, BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1, ContractWithCustomerLiability, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 26 | 2 | Ongoing |
| Material weakness in internal controls | high | 25 | 2 | Ongoing |
| Substantial doubt about ability to continue | high | 2 | 0 | NEW |
| Restatement of financial statements | high | 11 | 0 | NEW |
| Impairment charge | medium | 55 | 2 | Ongoing |
| Restructuring | medium | 56 | 4 | Ongoing |
| Off-balance sheet arrangements | medium | 26 | 2 | Ongoing |
| Related party transactions | low | 5 | 0 | NEW |
Filing signal breakdown
Red flags: 5
Positive: 1
Watch: 0
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $35.67B at $58.22 per share.
- ProPrice & TechnicalsPrice $58.22 — downtrend (below 200-DMA); 1-month momentum negative.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Elevated.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -16
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Kroger Co. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewMarket cap $35.67B at $58.22 per share..
Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow KR stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR● you | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |